We are also very enthusiastic about expanding our pipeline with additional movement disorder products in clinical development for multiple system atrophy (MSA) and Parkinson’s disease, through the strategic collaboration announced yesterday with MODAG GmbH." sales of AUSTEDO ®, our novel therapy for the treatment of patients with Huntington’s disease and tardive dyskinesia. Our results were driven by robust performance of AJOVY ® in the U.S., Europe and Japan as well as U.S. Kåre Schultz, Teva's President and CEO, said, "I am very happy with our solid performance in the third quarter of 2021, especially our strong cash flow and continued momentum with key brands. (NYSE and TASE: TEVA) today reported results for the quarter ended September 30, 2021. TEL AVIV, Israel-( BUSINESS WIRE)-Teva Pharmaceutical Industries Ltd.
0 kommentar(er)
